Within companion-animal oral solid dose manufacture, metronidazole veterinary API is incorporated into immediate-release tablets at label claims between 50 mg and 500 mg. The crystalline base has a melting endotherm of 159–163 °C, which permits conventional wet-granulation drying at 55–60 °C without polymorphic conversion. Flow and compressibility defects are managed by high-shear granulation in a top-driven mixer with an impeller speed of 200–400 rpm and a chopper speed of 1500–3000 rpm. A povidone K-30 binder solution at 3–5% w/w in purified water is added at 1.5–2.5% w/w of dry mass. The wet mass is dried in a fluid-bed dryer at inlet air temperature 55–60 °C until loss on drying is 0.8–1.5%. Milling through a 0.8 mm conical screen reduces oversized granules. The final blend includes crospovidone 2–4% w/w, sodium starch glycolate 2% w/w, colloidal silicon dioxide 0.5% w/w, and magnesium stearate 0.5% w/w screened through a 500 µm mesh. Compression on a rotary tablet press with 8–10 mm round biconvex tooling targets hardness 5–8 kp, friability below 1.0% by USP <1216>, and disintegration below 15 minutes by USP <701>. Dissolution testing uses USP <711> Apparatus 2 at 50 rpm in 900 mL of 0.1 N hydrochloric acid; release of not less than 80% at 30 minutes is the development target. Content uniformity follows USP <905> with acceptance value ≤15 for 10 tablets. Tablet splitting for dose adjustment is common in veterinary practice but introduces mass variability; a splitter validation study is recommended when the scored tablet is used below 25 mg. Published data for some veterinary-specific high-dose strength formulations is limited, so three-batch development runs are used to define final hardness and ejection force limits.

What Buffering Strategy Prevents Free Base Precipitation in Injectable Metronidazole?

Injectable dosage forms use metronidazole at 5 mg/mL in sterile water for injection or 0.9% sodium chloride. The imidazole nitrogen has a pKa near 2.4, leaving the unprotonated free base as the dominant species above pH 5.0, where aqueous solubility decreases and precipitation risk increases. The formulation is buffered with citric acid monohydrate and sodium citrate dihydrate to pH 4.5–5.5, which maintains solubility while limiting venous and tissue irritation. The solution is filtered through a 0.22 µm polyethersulfone or polyvinylidene fluoride membrane, filled into Type I glass or polyolefin containers under a nitrogen overlay, and terminally sterilized at 121 °C for 15 minutes. Metronidazole is comparatively stable in this pH range, but the finished solution must be protected from light because photodegradation of the nitroimidazole ring forms colored by-products. Sterile veterinary injections compounded under USP <797> are tested for particulate matter by USP <788>; a 100 mL solution should have no visible particles and meet the subvisible limits of 6000 particles per container for ≥10 µm and 600 for ≥25 µm. Osmolality is adjusted to approximately 285–310 mOsm/kg. The injection is incompatible with strongly alkaline vehicles or drugs such as sodium bicarbonate because free base precipitation occurs above pH 6.0. Published data for specific veterinary admixture compatibility with enrofloxacin-containing infusions is limited; visual precipitation screening is required before simultaneous administration through the same line. For extralabel use in companion animals, the human-approved injection is often the starting point, but pharmacy-compounded veterinary formulations require batch-level sterility and endotoxin control because metronidazole is not approved as a veterinary injectable in many jurisdictions.

Powder, granule, and premix development for metronidazole is constrained by the regulatory boundary for food-producing species. In the European Union, metronidazole is listed among substances without a maximum residue limit and is prohibited in food-producing animals; in the United States, the Food and Drug Administration prohibits extra-label use of nitroimidazoles in food-producing species under 21 CFR 530.41. Consequently, oral powders and granules are manufactured only for dogs, cats, laboratory non-food animals, ornamental fish, and other species not entering the human food chain. Powder blending for veterinary dispensing uses geometric dilution of micronized metronidazole with lactose monohydrate or microcrystalline cellulose through a 30-mesh sieve, followed by low-shear V-blender mixing at 60–70% vessel fill. Homogeneity is assessed by sampling 10 positions and requiring relative standard deviation ≤5.0%. Granule manufacture uses extrusion-spheronization with a screen aperture of 0.8 mm, spheronizer speed of 800–1200 rpm, and drying at 50 °C to moisture ≤2.0%. The resulting pellets have bulk density 0.55–0.70 g/mL; published data for this specific configuration is limited and should be verified by batch-scale trials. Premix-like carriers containing metronidazole cannot legally be designated as feed additives in EU or US food-animal production; facility segregation, batch records, and labeling must state the non-food-animal restriction. If a premix is produced for ornamental fish or zoological animals, the same carrier blend is prepared with 0.5–2.0% w/w fumed silica to reduce segregation. Sodium metabisulfite at 0.1% w/w may be considered as an antioxidant only after compatibility confirmation, because sulfites can react with the nitro group and reduce assay.

When Metronidazole Is Compounded into Low-pH Otic Drops with Enrofloxacin or Ketoconazole

Otic solutions for chronic canine and feline otitis externa are compounded from veterinary-grade metronidazole base, enrofloxacin or marbofloxacin, and ketoconazole or miconazole in a low-water or anhydrous vehicle. The raw material may be described as compound metronidazole ear drops veterinary grade API, but compounding pharmacies treat the input as metronidazole base with defined particle size and related substance attributes. The metronidazole concentration is commonly 0.5–1.0% w/v; enrofloxacin 0.5–1.0% w/v; ketoconazole 1.0–2.0% w/v. The vehicle uses propylene glycol, ethanol 96%, and polyethylene glycol 400 to maintain solubility and reduce free-base precipitation. pH is adjusted with glacial acetic acid or citric acid to 4.0–5.0; below 3.5, irritation risk increases, and above 5.5, metronidazole precipitation risk increases. Micronization by air-jet mill to D90 below 25 µm is used when the API is suspended rather than fully dissolved. The compounded product is packaged in amber glass or high-density polyethylene bottles with dropper tips because nitroimidazoles degrade under light. The beyond-use date assigned without a stability-indicating HPLC study is 14 days at controlled room temperature or 30 days refrigerated under USP <795>. Batch release includes pH measurement, resuspendability evaluation, and visual absence of agglomerates before dispensing. Published data for the long-term chemical stability of metronidazole in combination with enrofloxacin and ketoconazole is limited; a stability-indicating method with retention time resolution of the three actives is required before extended beyond-use dating.

Capsule Dilution, Segregation Control, and Content Uniformity in Low-Dose Veterinary Units

Because tablet splitting below 50 mg introduces unacceptable mass variation in small companion animals, metronidazole API is diluted into capsule formulations containing 5–25 mg per unit. The API is triturated with lactose monohydrate 200 mesh in 1:1 or 1:10 geometric steps to form the final blend. The blend is screened through a 30-mesh sieve and mixed in a low-shear blender at 25 rpm for 10 minutes. Content uniformity is tested under USP <905> with acceptance value ≤15; individual capsule fill weight RSD should not exceed 4.0%. Because metronidazole crystals have a higher density than lactose, segregation can occur during high-speed filling; maintaining API D90 ≤75 µm and adding 0.5% w/w colloidal silicon dioxide reduces this. Hard gelatin capsules are filled to target fill weight with a dosator or tamping pin machine; HPMC capsules are used where moisture-sensitive shells are unavoidable, but fill and storage relative humidity should remain below 40%. Dissolution testing for capsules follows USP <711> Apparatus 1 at 100 rpm in 900 mL of 0.1 N hydrochloric acid because the shell does not delay metronidazole release beyond 10 minutes under these conditions. Published data for specific veterinary capsule formulations is limited, so fill weight and blend uniformity parameters are confirmed by a three-batch development study.

Suspension Vehicles for Exotic Species Must Balance pH, Viscosity, and Osmolality

For avian, reptile, and small-mammal patients requiring oral liquid dosing, metronidazole suspensions are prepared at 25 mg/mL or 50 mg/mL. The vehicle combines purified water with a suspending agent such as sodium carboxymethylcellulose 0.5–1.0% w/v or xanthan gum 0.3–0.5% w/v. Target viscosity is 100–300 mPa·s at 25 °C to permit withdrawal through a small-diameter dosing syringe while maintaining suspension uniformity. pH is buffered to 4.5–5.5 with citrate buffer; this range minimizes free base precipitation and limits irritation to oral mucosa. Osmolality is adjusted with sorbitol or glycerin when the preparation is intended for crop administration in birds; published data for specific osmolality tolerance in reptiles is limited, but hypotonic to isotonic values are generally preferred. The suspension is stored in amber polyethylene terephthalate bottles protected from light and assigned a beyond-use date of 14 days refrigerated under USP <795> unless a stability study supports a longer period. Physical stability is evaluated by phase separation after 24 hours; suspensions that settle more than 10% by volume require reformulation with a higher yield stress. Sucrose-containing vehicles are avoided where extended stability is required because reducing sugar impurities may reduce the nitro group under long-term storage.